• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Doerr L John

    6/7/23 4:59:38 PM ET
    $AMRS
    Major Chemicals
    Industrials
    Get the next $AMRS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    DOERR L JOHN

    (Last) (First) (Middle)
    C/O 1180 SAN CARLOS AVENUE, #717

    (Street)
    SAN CARLOS CA 94070

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    AMYRIS, INC. [ AMRS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/05/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    2019 LSA $3 06/05/2023 D $63,014,396.78 06/05/2023 07/01/2023 Common Stock 21,004,799 (3)(4) 0 I By Foris Ventures, LLC(1)(2)
    2019 LSA $3 06/05/2023 A $63,014,396.78 06/05/2023 07/01/2024 Common Stock 21,004,799 (3)(4) $63,014,396.78 I By Foris Ventures, LLC(1)(2)
    1. Name and Address of Reporting Person*
    DOERR L JOHN

    (Last) (First) (Middle)
    C/O 1180 SAN CARLOS AVENUE, #717

    (Street)
    SAN CARLOS CA 94070

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Foris Ventures, LLC

    (Last) (First) (Middle)
    1180 SAN CARLOS AVENUE, #717

    (Street)
    SAN CARLOS CA 94070

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Doerr Ann Howland

    (Last) (First) (Middle)
    1180 SAN CARLOS AVENUE, #717

    (Street)
    SAN CARLOS CA 94070

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Hager Barbara

    (Last) (First) (Middle)
    1180 SAN CARLOS AVENUE, #717

    (Street)
    SAN CARLOS CA 94070

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Vallejo Ventures Trust UTA 21296

    (Last) (First) (Middle)
    1180 SAN CARLOS AVENUE, #717

    (Street)
    SAN CARLOS CA 94070

    (City) (State) (Zip)
    Explanation of Responses:
    1. L. John Doerr ("John Doerr ") indirectly holds all of the membership interests in Foris Ventures, LLC ("FV"). John Doerr disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
    2. Barbara Hager, the manager of FV, may be deemed to have sole power to vote and dispose of the shares held by FV. The Vallejo Ventures Trust U/T/A 2/12/96 ("VVT"), the member of FV, may be deemed to have sole power to vote and dispose of these securities and John Doerr and Ann Doerr, the trustees of VVT, and Barbara Hager, the special trustee of VVT, may be deemed to have shared power to vote and dispose of the reported securities. Each of John Doerr , Ann Doerr and Barbara Hager disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. FV and VVT are represented on the Issuer's board of directors by John Doerr. Accordingly, each of Ann Doerr, Barbara Hager, FV and VVT are deemed to be a director by deputization.
    3. On June 5, 2023, FV entered into that certain Omnibus Amendment Agreement, dated as of June 5, 2023 (the "Omnibus Amendment Agreement"), with the Issuer and the other parties thereto, to that certain Amended and Restated Loan and Security Agreement, dated as of October 28, 2019, by and between the Issuer, FV and the other parties thereto (as amended and restated from time to time, the "2019 LSA"). The Omnibus Amendment Agreement amended the 2019 LSA to extend the maturity date from July 1, 2023 to July 1, 2024, among other things. As of June 5, 2023, 16,680,334 shares of the issuer's common stock (the "Common Stock") are issuable upon conversion of the 2019 LSA in respect of an outstanding principal amount of $50.0 million and 4,324,465 shares of Common Stock are issuable upon conversion of accrued and unpaid interest of $13.0 million, reflecting a fixed conversion price of $3.00 per share of Common Stock.
    4. (Continued from Footnote 3) The 2019 LSA accrues interest at 6% per annum, subject to certain default interest provisions in the event of a default under the 2019 LSA.
    Remarks:
    /s/ L. John Doerr, by Barbara Hager as his attorney in fact 06/07/2023
    /s/ Ann Howland Doerr, by Barbara Hager as her attorney in fact 06/07/2023
    /s/ Vallejo Ventures Trust UTA 21296, by Barbara Hager as Special Trustee 06/07/2023
    /s/ Foris Ventures, LLC, by Barbara Hager as manager 06/07/2023
    /s/ Barbara Hager 06/07/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AMRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRS

    DatePrice TargetRatingAnalyst
    5/18/2023$3.10 → $0.65Buy → Hold
    Jefferies
    5/10/2023$4.00 → $1.25Outperform → Market Perform
    TD Cowen
    4/28/2023$1.50Buy
    Canaccord Genuity
    11/10/2022Overweight → Neutral
    JP Morgan
    11/9/2022Outperform → Perform
    Oppenheimer
    8/10/2022$4.00 → $2.00Buy → Neutral
    ROTH Capital
    6/24/2022Neutral
    JP Morgan
    5/25/2022$2.50Neutral
    Piper Sandler
    More analyst ratings

    $AMRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION

      Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris" or the "Company"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.

      8/9/23 9:38:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

      EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce

      6/26/23 9:10:00 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Financials

    Live finance-specific insights

    See more
    • AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9

      EMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo, President

      5/2/23 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

      Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior yearFull year Consumer revenue of $176.9 million increased 92% and outperformed prestige beauty industry growth of 15%. Core revenue of $269.8 million grew 44% over prior yearUse of cash for operating and investing activities sequentially improved each quarter; Q4 2022 down $102 million versus Q1 2022Actions taken to simplify portfolio, streamline management structure and deliver efficienciesEMERYVILLE, Calif., March 15, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating th

      3/15/23 4:11:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 15, 2023

      EMERYVILLE, Calif., Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2022, on the afternoon of Wednesday, March 15, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during wh

      2/28/23 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:14:56 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:11:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:12:50 PM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Leadership Updates

    Live Leadership Updates

    See more

    $AMRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

      EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce

      6/26/23 9:10:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES APPOINTMENT OF ANA DUTRA TO BOARD OF DIRECTORS

      EMERYVILLE, Calif., Jan. 27, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced the appointment of Ms. Ana Dutra as its newest independent member of the Amyris Board of Directors, effective January 21, 2022. "We are very pleased to welcome Ana as a new, independent director to Amyris," said John Melo, President and Chief Executive Officer of Amyris. "Ana brings decades of leadership, operational depth and highly re

      1/27/22 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form 3 filed by new insider White J. Scott

      3 - AMYRIS, INC. (0001365916) (Issuer)

      9/20/23 8:09:50 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form 3 filed by new insider Gund Philip J.

      3 - AMYRIS, INC. (0001365916) (Issuer)

      8/17/23 7:35:56 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form 3 filed by new insider Reiss M. Freddie

      3 - AMYRIS, INC. (0001365916) (Issuer)

      8/17/23 7:32:49 PM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amyris downgraded by Jefferies with a new price target

      Jefferies downgraded Amyris from Buy to Hold and set a new price target of $0.65 from $3.10 previously

      5/18/23 7:22:16 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • Amyris downgraded by TD Cowen with a new price target

      TD Cowen downgraded Amyris from Outperform to Market Perform and set a new price target of $1.25 from $4.00 previously

      5/10/23 7:29:32 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • Canaccord Genuity initiated coverage on Amyris with a new price target

      Canaccord Genuity initiated coverage of Amyris with a rating of Buy and set a new price target of $1.50

      4/28/23 7:13:42 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      1/5/24 4:22:57 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      12/14/23 4:34:27 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      10/16/23 4:41:27 PM ET
      $AMRS
      Major Chemicals
      Industrials